Related Experiment Videos
Lipoprotein (a): an emerging risk factor for atherosclerosis
1Howard Hughes Medical Institute, University of Utah, Salt Lake City.
The Canadian Journal of Cardiology
|June 1, 1989
Summary
Elevated levels of Lipoprotein (a), a variant of low-density lipoprotein, significantly increase the risk of atherosclerosis. Its protein, apolipoprotein (a), resembles plasminogen, suggesting a role in linking lipoprotein and coagulation systems.
Area of Science:
- Cardiovascular biology
- Lipid metabolism
- Thrombosis research
Background:
- Lipoprotein (a) [Lp(a)] is a plasma lipoprotein associated with increased risk of atherosclerosis.
- Epidemiologic studies consistently link Lp(a) levels >0.20 g/L to higher risks of coronary and cerebrovascular disease.
- The precise function and atherogenic mechanisms of Lp(a) have remained largely unclear.
Purpose of the Study:
- To elucidate the functional role and atherogenic potential of Lipoprotein (a).
- To investigate the molecular basis of Lp(a)'s contribution to cardiovascular disease.
Main Methods:
- Molecular biology techniques to analyze apolipoprotein (a).
- Comparison of apolipoprotein (a) structure with plasminogen.
- Review of emerging evidence linking lipoprotein and coagulation pathways.
Main Results:
- Apolipoprotein (a) shares structural similarities with plasminogen, the precursor to the anticoagulant enzyme plasmin.
- Emerging evidence suggests Lp(a) may bridge the lipoprotein and coagulation systems.
- Potential roles include cholesterol delivery to sites of vascular injury or inhibition of plasminogen activation during thrombus formation.
Conclusions:
- Lipoprotein (a) possesses a unique structure with implications for atherogenesis.
- Lp(a) may play a dual role in cardiovascular pathology by influencing both lipid deposition and thrombus stability.
- Further research into Lp(a) is crucial for understanding and potentially treating atherosclerosis.